On November 6, Thermo Fisher Scientific fell 3.08% in Regular Trading, trading at $684.41 with turnover of $6.61 billion.

The clearest recent catalyst in publicly available information is an analyst action: Evercore ISI lowered its price target on Thermo Fisher Scientific to $615 from $720 on October 28, a move that likely pressured near-term sentiment despite the company retaining a broader favorable Street profile.

The background is that Thermo Fisher Scientific reported third-quarter results on October 21 that beat expectations, with adjusted EPS of $6.68 versus the $6.40 consensus and revenue of $12.137 billion versus the $11.946 billion consensus. The company also indicated full-year revenue of $47.7 billion to $48.2 billion. Even so, the later target-price reduction stands out as the most direct recent event linked to the current weakness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)